

Jens T Siveke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6593376/publications.pdf>

Version: 2024-02-01

111
papers

5,819
citations

101384

36
h-index

82410

72
g-index

121
all docs

121
docs citations

121
times ranked

9005
citing authors

#	ARTICLE	IF	CITATIONS
1	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2016, 387, 545-557.	6.3	878
2	EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis. <i>Cancer Cell</i> , 2012, 22, 304-317.	7.7	445
3	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. <i>Nature Medicine</i> , 2015, 21, 1163-1171.	15.2	349
4	Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 13438-13443.	3.3	190
5	NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. <i>European Journal of Cancer</i> , 2019, 108, 78-87.	1.3	185
6	Notch Signaling Is Required for Exocrine Regeneration After Acute Pancreatitis. <i>Gastroenterology</i> , 2008, 134, 544-555.e3.	0.6	151
7	The Latest Developments in Imaging of Fibroblast Activation Protein. <i>Journal of Nuclear Medicine</i> , 2021, 62, 160-167.	2.8	143
8	Concomitant Pancreatic Activation of KrasG12D and Tgfa Results in Cystic Papillary Neoplasms Reminiscent of Human IPMN. <i>Cancer Cell</i> , 2007, 12, 266-279.	7.7	140
9	Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways. <i>Modern Pathology</i> , 2014, 27, 73-86.	2.9	127
10	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. <i>Cancer Discovery</i> , 2021, 11, 2780-2795.	7.7	125
11	Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. <i>Journal of Pathology</i> , 2012, 226, 723-734.	2.1	111
12	Inflammation-Induced NFATc1-STAT3 Transcription Complex Promotes Pancreatic Cancer Initiation by <i>Kras</i> G12D. <i>Cancer Discovery</i> , 2014, 4, 688-701.	7.7	108
13	Early Requirement of Rac1 in a Mouse Model of Pancreatic Cancer. <i>Gastroenterology</i> , 2011, 141, 719-730.e7.	0.6	105
14	Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?. <i>Gut</i> , 2017, 66, 168-179.	6.1	103
15	Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study. <i>Journal of Hepatology</i> , 2016, 65, 280-288.	1.8	98
16	Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology. <i>Gut</i> , 2012, 61, 1488-1500.	6.1	95
17	IKK β controls p52/RelB at the <i>skp2</i> gene promoter to regulate G1- to S-phase progression. <i>EMBO Journal</i> , 2006, 25, 3801-3812.	3.5	89
18	Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 128-138.	3.7	89

#	ARTICLE	IF	CITATIONS
19	Antithetical <sc>NFAT</sc> c1â€“Sox2 and p53â€“miR200 signaling networks govern pancreatic cancer cell plasticity. <i>EMBO Journal</i> , 2015, 34, 517-530.	3.5	87
20	Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience. <i>Annals of Surgical Oncology</i> , 2015, 22, 1212-1220.	0.7	77
21	Conditional ablation of Notch signaling in pancreatic development. <i>Development (Cambridge)</i> , 2008, 135, 2757-2765.	1.2	75
22	NFATc1 Links EGFR Signaling to Induction of Sox9 Transcription and Acinarâ€“Ductal Transdifferentiation in the Pancreas. <i>Gastroenterology</i> , 2015, 148, 1024-1034.e9.	0.6	73
23	Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner. <i>Nucleic Acids Research</i> , 2017, 45, 6334-6349.	6.5	73
24	The role of insulin and IGF system in pancreatic cancer. <i>Journal of Molecular Endocrinology</i> , 2013, 50, R67-R74.	1.1	70
25	Initial clinical experience with ⁹⁰Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262468.	2.8	64
26	Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1461-1470.	3.2	60
27	Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in <i>KRAS</i>-Mutant Pancreatic and Colorectal Cancer. <i>Cancer Research</i> , 2019, 79, 2367-2378.	0.4	60
28	PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancerâ€“a randomised biomarker-driven clinical phase II AIO study. <i>European Journal of Cancer</i> , 2018, 92, 11-19.	1.3	55
29	A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging. <i>European Radiology Experimental</i> , 2019, 3, 41.	1.7	55
30	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. <i>Lancet Oncology</i> , The, 2018, 19, e151-e160.	5.1	51
31	A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy. <i>PLoS ONE</i> , 2019, 14, e0218642.	1.1	48
32	Fibroblast-Activating Protein: Targeting the Roots of the Tumor Microenvironment. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1412-1414.	2.8	47
33	Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities. <i>Clinical Cancer Research</i> , 2022, 28, 4346-4353.	3.2	45
34	Covalentâ€“Allosteric Inhibitors to Achieve Akt Isoformâ€“Selectivity. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 18823-18829.	7.2	44
35	Conditional inactivation of Myc impairs development of the exocrine pancreas. <i>Development (Cambridge)</i> , 2008, 135, 3191-3196.	1.2	42
36	Knockdown of myeloid cell hypoxia-inducible factor-1Î± ameliorates the acute pathology in DSS-induced colitis. <i>PLoS ONE</i> , 2017, 12, e0190074.	1.1	42

#	ARTICLE	IF	CITATIONS
37	Identification of Epidermal Pdx1 Expression Discloses Different Roles of Notch1 and Notch2 in Murine KrasG12D-Induced Skin Carcinogenesis In Vivo. <i>PLoS ONE</i> , 2010, 5, e13578.	1.1	36
38	Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma. <i>Oncolmmunology</i> , 2015, 4, e1029698.	2.1	36
39	Context-Dependent Epigenetic Regulation of Nuclear Factor of Activated T Cells 1 in Pancreatic Plasticity. <i>Gastroenterology</i> , 2017, 152, 1507-1520.e15.	0.6	36
40	Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. <i>European Journal of Cancer</i> , 2019, 106, 24-33.	1.3	36
41	Image-Based Molecular Phenotyping of Pancreatic Ductal Adenocarcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 724.	1.0	35
42	Proton Irradiation Increases the Necessity for Homologous Recombination Repair Along with the Indispensability of Non-Homologous End Joining. <i>Cells</i> , 2020, 9, 889.	1.8	35
43	Characterization of a dual <scp>BET</scp>/<scp>HDAC</scp> inhibitor for treatment of pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2020, 147, 2847-2861.	2.3	34
44	Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene. <i>Oncotarget</i> , 2017, 8, 33393-33404.	0.8	33
45	TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer. <i>Cell Death Discovery</i> , 2020, 6, 12.	2.0	30
46	MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. <i>Nature Communications</i> , 2021, 12, 5505.	5.8	30
47	Implementing cell-free DNA of pancreatic cancer patientâ€™ derived organoids for personalized oncology. <i>JCI Insight</i> , 2020, 5, .	2.3	30
48	Selective <i>In Vivo</i> Imaging of Syngeneic, Spontaneous, and Xenograft Tumors Using a Novel Tumor Cellâ€™ Specific Hsp70 Peptide-Based Probe. <i>Cancer Research</i> , 2014, 74, 6903-6912.	0.4	28
49	Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression. <i>Nature Communications</i> , 2021, 12, 3895.	5.8	28
50	Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCII expression. <i>Nature Communications</i> , 2022, 13, 156.	5.8	28
51	Modeling Therapy Response and Spatial Tissue Distribution of Erlotinib in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1145-1152.	1.9	27
52	Hes1 Controls Exocrine Cell Plasticity and Restricts Development of Pancreatic Ductal Adenocarcinoma in a Mouse Model. <i>American Journal of Pathology</i> , 2016, 186, 2934-2944.	1.9	26
53	Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma. <i>Scientific Reports</i> , 2017, 7, 17038.	1.6	26
54	Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma. <i>Oncogene</i> , 2020, 39, 4770-4779.	2.6	26

#	ARTICLE	IF	CITATIONS
55	Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. <i>British Journal of Cancer</i> , 2017, 116, 1462-1469.	2.9	25
56	Direct Molecular Tissue Analysis by MALDI Imaging Mass Spectrometry in the Field of Gastrointestinal Disease. <i>Gastroenterology</i> , 2012, 143, 544-549.e2.	0.6	24
57	Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial. <i>European Journal of Cancer</i> , 2018, 105, 71-78.	1.3	24
58	Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer. <i>Cancers</i> , 2020, 12, 353.	1.7	24
59	Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis. <i>Cell Reports</i> , 2021, 37, 110056.	2.9	24
60	Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer – A subgroup analysis of the pivotal NAPOLI-1 trial. <i>Journal of Geriatric Oncology</i> , 2019, 10, 427-435.	0.5	23
61	Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group – Molecular Diagnostics and Therapy™. <i>European Journal of Cancer</i> , 2020, 135, 1-7.	1.3	23
62	A Novel Approach for Image-Guided 131I Therapy of Pancreatic Ductal Adenocarcinoma Using Mesenchymal Stem Cell-Mediated NIS Gene Delivery. <i>Molecular Cancer Research</i> , 2019, 17, 310-320.	1.5	22
63	Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 62-75.	0.5	22
64	Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). <i>International Journal of Cancer</i> , 2020, 147, 2493-2502.	2.3	22
65	KRAS above and beyond - EGFR in pancreatic cancer. <i>Oncotarget</i> , 2012, 3, 1262-1263.	0.8	21
66	Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer. <i>Cancers</i> , 2019, 11, 1068.	1.7	19
67	N-Myc-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastoma. <i>Scientific Reports</i> , 2020, 10, 7157.	1.6	19
68	Membranous CD24 drives the epithelial phenotype of pancreatic cancer. <i>Oncotarget</i> , 2016, 7, 49156-49168.	0.8	19
69	Integrin-Targeted Hybrid Fluorescence Molecular Tomography/X-ray Computed Tomography for Imaging Tumor Progression and Early Response in Non-Small Cell Lung Cancer. <i>Neoplasia</i> , 2017, 19, 8-16.	2.3	17
70	Surgery for Cystic Pancreatic Lesions in the Post-Sendai Era: A Single Institution Experience. <i>HPB Surgery</i> , 2015, 2015, 1-5.	2.2	16
71	The transcription factor FLI1 promotes cancer progression by affecting cell cycle regulation. <i>International Journal of Cancer</i> , 2020, 147, 189-201.	2.3	16
72	Cellular model system to dissect the isoform-selectivity of Akt inhibitors. <i>Nature Communications</i> , 2021, 12, 5297.	5.8	16

#	ARTICLE	IF	CITATIONS
73	A randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4-4.	0.8	16
74	PAXgene fixation enables comprehensive metabolomic and proteomic analyses of tissue specimens by MALDI MSI. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2018, 1862, 51-60.	1.1	14
75	A BAP1 synonymous mutation results in exon skipping, loss of function and worse patient prognosis. <i>IScience</i> , 2021, 24, 102173.	1.9	13
76	Chromosomal instability in mouse metastatic pancreatic cancerâ€™itâ€™s Kras and Tp53 after all. <i>Cancer Cell</i> , 2005, 7, 405-407.	7.7	12
77	Notch-Induced Myeloid Reprogramming in Spontaneous Pancreatic Ductal Adenocarcinoma by Dual Genetic Targeting. <i>Cancer Research</i> , 2018, 78, 4997-5010.	0.4	11
78	MEK Inhibition Targets Cancer Stem Cells and Impedes Migration of Pancreatic Cancer Cells<i>In Vitro</i>and<i>In Vivo</i>. <i>Stem Cells International</i> , 2019, 2019, 1-11.	1.2	11
79	Serial Circulating Tumor DNA Mutational Status in Patients with <i>KRAS</i>-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial. <i>Clinical Chemistry</i> , 2020, 66, 1510-1520.	1.5	11
80	Poly(<sc>ADP</sc>â€™ribose) polymerase inhibition in pancreatic cancer. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 373-384.	1.5	11
81	Hyperpolarized ¹³ C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC. <i>Scientific Reports</i> , 2021, 11, 1191.	1.6	11
82	Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6727.	1.8	11
83	[¹⁸ F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. <i>EJNMMI Research</i> , 2021, 11, 70.	1.1	11
84	Oncogenic KRas-induced Increase in Fluid-phase Endocytosis is Dependent on N-WASP and is Required for the Formation of Pancreatic Preneoplastic Lesions. <i>EBioMedicine</i> , 2017, 15, 90-99.	2.7	10
85	Anti-leukemic effect of CDK9 inhibition in T-cell polymphocytic leukemia. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072093376.	1.1	10
86	Mir34a constrains pancreatic carcinogenesis. <i>Scientific Reports</i> , 2020, 10, 9654.	1.6	10
87	Nanoliposomal Irinotecan in the Clinical Practice Guideline for Metastatic Pancreatic Cancer: Applicability to Clinical Situations. <i>Journal of Clinical Oncology</i> , 2017, 35, 689-690.	0.8	9
88	Current Methods in Mouse Models of Pancreatic Cancer. <i>Methods in Molecular Biology</i> , 2015, 1267, 185-215.	0.4	9
89	Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1. <i>Pancreatology</i> , 2021, 21, 192-199.	0.5	8
90	Panitumumab in combination with gemcitabine/cisplatin (GemCis) for patients with advanced kRAS WT biliary tract cancer: A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4082-4082.	0.8	8

#	ARTICLE	IF	CITATIONS
91	18F-fluorothymidine PET for predicting survival in patients with resectable pancreatic cancer. <i>Oncotarget</i> , 2018, 9, 10128-10134.	0.8	8
92	Covalent allosteric Inhibitors to Achieve Akt Isoform Selectivity. <i>Angewandte Chemie</i> , 2019, 131, 18999-19005.	1.6	7
93	FOLFIRI plus sunitinib versus FOLFIRI alone in advanced chemorefractory esophagogastric cancer patients: A randomized placebo-controlled multicentric AIO phase II trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4086-4086.	0.8	7
94	Combined multimodal ctDNA analysis and radiological imaging for tumor surveillance in Non-small cell lung cancer. <i>Translational Oncology</i> , 2022, 15, 101279.	1.7	7
95	Localized Angiosarcoma, Not One Disease: A Retrospective Single-Center Study on Prognosis Depending on the Primary Site and Etiology. <i>Sarcoma</i> , 2021, 2021, 1-10.	0.7	6
96	Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4540-4540.	0.8	6
97	Loss of Wasl improves pancreatic cancer outcome. <i>JCI Insight</i> , 2020, 5, .	2.3	5
98	Resminostat in advanced hepatocellular carcinoma (HCC): Overall survival subgroup analysis of prognostic factors in the SHELTER trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15088-e15088.	0.8	5
99	ECC Scoring for the Evaluation of Therapy-Naïve Cancer Patients to Predict Cardiotoxicity. <i>Cancers</i> , 2021, 13, 1197.	1.7	4
100	Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4115-4115.	0.8	4
101	Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB). <i>JAMA Oncology</i> , 2022, 8, 929.	3.4	4
102	The clinical utility of <sc>cfRNA</sc> for disease detection and surveillance: A proof of concept study in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 2180-2191.	0.8	4
103	Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma. <i>EJNMMI Research</i> , 2021, 11, 120.	1.1	3
104	MCL1 as putative target in pancreatoblastoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 265-272.	1.4	3
105	Next-generation metabolic imaging in pancreatic cancer. <i>Gut</i> , 2016, 65, 367-369.	6.1	2
106	Antitumor immune response is associated with favorable survival in GEP-NEN G3. <i>Endocrine-Related Cancer</i> , 2021, 28, 683-693.	1.6	2
107	ACCEPT: Afatinib as cancer therapy for exocrine pancreatic tumorsâ€“An explorative randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4150-TPS4150.	0.8	2
108	RE: Proteomic Mucin Profiling for the Identification of Cystic Precursors of Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju263-dju263.	3.0	1

#	ARTICLE	IF	CITATIONS
109	Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer. <i>OncImmunology</i> , 2022, 11, 2043037.	2.1	1
110	Klinische Manifestationen zystischer Pankreasneoplasien. , 2013, , 271-276.		0
111	Phosphorylated ERK (pERK) as biomarker in patients with advanced pancreatic cancer treated with erlotinib within a randomized phase III trial (AIO-PK0104).. <i>Journal of Clinical Oncology</i> , 2013, 31, 189-189.	0.8	0